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Fibroblast growth factor (FGF)-21, a member of the FGF family, is a novel hormone
involved in the control of metabolism by modulating glucose homeostasis, insulin
sensitivity, ketogenesis, and promoting adipose tissue “browning.” Recent studies
demonstrated that brown adipose tissue is not only a target for FGF-21, but is also a
potentially important source of systemic FGF-21. These findings support the hypothesis
that FGF-21 plays a physiologic role in thermogenesis and thermogenic recruitment of
white adipose tissue by an autocrine–paracrine axis. This review examines the role of
FGF-21 in thermogenesis from the perspective of cell-based, animal model, and human
studies. We also present recent advances in the characterization of FGF-21’s regulation
of metabolism.
Keywords: FGF-21, fibroblast growth factor receptor, brown adipose tissue, metabolism, thermogenesis

Introduction
Fibroblast growth factors (FGFs) are a large family of polypeptide growth factors comprised of 22
different members, with molecular masses ranging from 17 to 34 kDa sharing 13–71% amino acid
identity. Among vertebrate species, FGFs are highly conserved in both gene structure and amino acid
sequence (1). FGF-21 is a novel member of the FGF family and is predominantly expressed in the
liver (2). FGF-21 activity depends on the membrane protein beta-klotho, a co-receptor with a very
short cytoplasmic domain. FGF-21 binds beta-klotho with its C-terminus and directly interacts with
FGF receptors (FGFRs) through its N-terminus, resulting in FGFR activation (3). During the past
decade, FGF-21 has been shown to be a novel regulator of metabolism and a potential therapeutic
target for the treatment of obesity and diabetes (4).
Adipose tissue is one of the main targets of FGF-21 action, and mammals have at least two different types of fat: white and brown. White adipose tissue (WAT) is the primary site of energy storage
and of release of hormones and cytokines that modulate whole-body metabolism and insulin resistance (5, 6). Brown adipose tissue (BAT) is not only an important body defense against hypothermia
but also plays a role in diet-induced thermogenesis (7). This energy expenditure is in the form of
thermogenesis, and is mediated by the expression of uncoupling protein 1 (UCP1). Hence, BAT
can regulate whole-body metabolism and may alter insulin sensitivity and modify susceptibility to
weight gain (8, 9).

FGF-21-Induced Thermogenesis in Mice
The first study of FGF-21’s function on mouse core body temperature was performed in 2005 by
Kharitonenkov and colleagues (4). Transgenic mice expressing human FGF-21 under the control
of an APOE promoter and wild-type littermates were fed a high-fat/high-carbohydrate diet for
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15 weeks. FGF-21 transgenic mice were resistant to high-fat dietinduced obesity and their BAT was denser. At room temperature,
FGF-21 transgenic mice had significantly lower body weight,
fasting glucose levels and leptin levels, despite a much higher
food intake compared to wild-type littermates. These data suggest that in a fed state, FGF-21 probably stimulates EE partially
through increased BAT activation, which in turn results in an
improved metabolism.
A study on the role of the peroxisome proliferator-activated
receptor alpha (PPAR-alpha)/FGF-21 endocrine signaling
pathway found that FGF-21 could reduce physical activity and
promote torpor, a short-term hibernation-like state of regulated
hypothermia that conserves energy (10). This was due to direct
FGF-21 induction by PPAR-alpha in response to fasting, and pharmacologically by PPAR-alpha agonists. FGF-21, in turn, stimulated lipolysis in WAT and ketogenesis in the liver. In contrast to
the previous study by Kharitonenkov and colleagues (4), the body
temperatures of FGF-21 transgenic mice in this study were 1–2°C
lower than their wild-type littermates. To examine whether core
body temperature was also affected under conditions in which
endogenous FGF-21 was increased, wild-type mice were infected
with an FGF-21 expressing adenovirus. Administration of FGF21 resulted in reductions in both basal and fasting-induced body
temperature. In addition to the reduced core body temperature,
locomotor activity was also dramatically reduced in FGF-21
transgenic mice. These data suggest that during fasting states,
FGF-21 may alter behavior to conserve energy.
Coskun et al. investigated the role of FGF-21 in obese mice
(11). Systemic administration of FGF-21 for 2 weeks in dietinduced obese mice and ob/ob mice lowered body weight by
20%, predominantly via a reduction in adiposity. In this study,
FGF-21-treated animals exhibited increased EE, fat utilization,
and lipid excretion, reduced hepatosteatosis, and ameliorated
hyperglycemia. In contrast to previous studies, no decrease in
total caloric intake or an effect on physical activity levels were
observed. After continuous infusion with FGF-21 (1 mg/kg/day)
for 5 days, a small but significant elevation of core body temperature was observed 4 h after initiation of treatment, lasting
for approximately 10 h. FGF-21 also increased EE during both
light and dark cycles, and depressed the respiratory quotient
(RQ) in the dark cycles. The results of this study contrasts with
an earlier report (10) where a reduction in body temperature was
observed. It is important to note that in the former study, obese
animals with ad libitum access to food were used and the body
temperatures were measured in the fed state. Lower core body
temperatures were only observed in lean, starved, and therefore
energy-deprived FGF-21 transgenic mice and no such effects
were reported in fed animals. Collectively, the data indicate a
divergent effect of FGF-21 on core temperature, driven by the
fed/fasting state.
Subsequently, Hondares and colleagues investigated the
thermogenic effect of FGF-21 on newborn mice (12). This
manuscript for the first time provided evidence suggesting that
a metabolic regulator hormone, produced by the liver, could
directly mediate activation of brown fat thermogenesis during
the fetal-to-neonatal transition. The authors found low levels
of FGF-21 in the plasma of fetal mice. After birth, however,
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plasma FGF-21 levels increased rapidly and remained high for
6 days before declining. Once weaning had completed, FGF21 levels were similar to adult mice. Similarly, Fgf21 mRNA
levels in both fetal and newborn mouse liver were low. Soon
after birth, Fgf21 was induced rapidly in the liver, with plasma
FGF-21 levels reaching that of adults within 16 h. To assess
whether activation of PPAR-alpha could mediate the action of
milk lipids on the Fgf21 gene, the authors studied PPAR-alpha
null pups. Expression of Fgf21 at birth in the liver of PPARalpha null mice was lower than their wild-type littermates.
Moreover, postnatal induction of the Fgf21 gene mediated
by milk intake was completely suppressed in PPAR-alpha
null pups. In wild-type pups starved after birth, injection of
the PPAR-alpha agonist, pirinixic acid (Wy14,643) induced
a significant increase in Fgf21 expression levels in the liver,
whereas no such response was achieved in PPAR-alpha null
pups. These results, consistent with previous observations (10),
indicate that PPAR-alpha is necessary for Fgf21 induction in
a fasting state.
Conversely, Hondares et al. (12) also found that FGF-21
could cause thermogenic activation of BAT in newborn mice
and cultured brown adipocytes. The expression of thermogenic
activation-related genes was increased in neonatal BAT after
birth, in parallel with the rise in plasma FGF-21 levels. This study
also treated neonate pups with a single dose of recombinant
mouse FGF-21 4 h after birth, without further suckling. A small,
but statistically significant reduction of blood glucose in the
absence of differences in free fatty acids or β-hydroxybutyrate
levels was observed. FGF-21 significantly induced the expression of genes encoding proteins involved in mitochondrial
oxidation and BAT thermogenic activation, such as Pgc-1α,
Ucp1, Dio2, Cyt c, Lipe, Glut1, and Glut4. Additionally, FGF-21
also increased the protein levels of peroxisome proliferatoractivated receptor γ, coactivator 1α (PGC-1α), UCP1, and
Cytochrome c. Moreover, PPAR-alpha null pups exhibited a
reduced postnatal induction of thermogenic genes, which was
rescued with FGF-21 treatment immediately after birth. Taken
together, these results (12) confirm the role of PPAR-alpha in
Fgf-21 induction and FGF-21 activation of BAT thermogenesis
in neonatal mice.
To assess whether FGF-21 may act directly on BAT, mouse
brown adipocytes were differentiated in culture and were then
exposed to FGF-21. At 5 nM, FGF-21 significantly induced
the expression of genes involved in thermogenic activation
(Pgc-1α, Ucp1, Glut4, Cyt c), while a higher concentration of
FGF-21 (50 nM) did not further enhance these effects. Finally,
mitochondrial function assays demonstrated that FGF-21 caused
a significant increase in brown adipocyte oxygen consumption.
FGF-21 treatment increased oligomycin-resistant uncoupled
phosphorylation, and resulted in a significant induction (roughly
threefold) of glucose oxidation in brown adipocytes. Additionally,
these data indicated that FGF-21 specifically targets BAT thermogenic activation and that in neonates, this may contribute to
neonatal activation of BAT thermogenesis in response to the start
of milk intake. Collectively, these studies in mice demonstrate
that FGF-21 is an important regulator of metabolism during
fasting and fed states.
2
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Direct Release of FGF-21 by Brown
Adipose Tissue

cAMP-mediated activation of PKA and p38 MAPK pathways and
induction of Fgf21 gene expression.
The authors also used HIB-1B cells [a brown adipocyte cell line
derived from a transgenic mouse brown fat tumor (15)] to further
investigate how Fgf21 gene transcription was regulated. HIB-1B
cells were co-transfected with a luciferase reporter construct with
a Fgf21 gene promoter and active form of PKA. By treating with
dibutyryl cAMP, a significant increase in Fgf21 promoter activity
was found. Furthermore, both active (MKK6-Glu) and inactive
(MKK6-K82A) forms of the upstream inducer of p38 MAPK,
MKK6, were tested for their role in Fgf21 promoter activity. Only
MKK6-Glu could significantly induce Fgf21 promoter activity
after transfection in the cell, which indicated that PKA-mediated
activation of Fgf21 transcription is p38 MAPK dependent.
Additionally, in a chromatin immunoprecipitation experiment, a
very strong binding of ATF2 (cyclic AMP-dependent transcription factor) to the Fgf21 promoter was observed, suggesting that
cAMP can promote this binding event in brown adipocytes. These
data provide a link between sympathetic activation during cold
stress and the release of FGF-21 from brown adipocytes. Finally,
this study also demonstrates that ATF2 binding to the Fgf21 gene
promoter is essential for cAMP-dependent induction of Fgf21
gene transcription. Further studies investigating the binding of
ATF2 to the Fgf21 promoter may reveal novel regulators and the
role of histone remodeling in Fgf21 induction.

Although the liver is a well-known site for FGF-21 generation
(2), Hondares et al. studied whether thermogenic activation in
adult mice could directly induce FGF-21 expression and release
in BAT (13). In this study, adult male mice were exposed to a 4°C
housing environment for 6 or 24 h. This cold exposure caused a
remarkable increase (40-fold) in Fgf21 expression levels in BAT.
Chronic acclimation to 4°C over 30 days also resulted in a significant induction of Fgf21 expression. In contrast, Fgf21 expression
levels were not significantly increased in the livers of mice acutely
exposed to cold and were even reduced in mice acclimated to
cold during a 30-day exposure. In mice exposed to cold for 24 h,
a modest increase in Fgf21 mRNA was observed in WAT. Thus,
whereas Fgf21 mRNA levels in BAT at thermoneutrality were
lower than in the liver and WAT, after thermogenic activation,
BAT showed the highest levels of Fgf21 mRNA expression.
Plasma levels of FGF-21 in mice did not change after 6 h, but
increased after 24 h of cold exposure, and increased even further
after a 30-day cold acclimation period. The authors also found
that there were significant negative arteriovenous gradients in
FGF-21 concentration across interscapular BAT from rats after
short term (24 h) cold exposure and long term (30 day) acclimation to cold exposure, demonstrating a significant FGF-21
output from BAT. Very recently, Keipert and colleagues showed
that in UCP-1 knockout mice, cold exposure induces a dramatic
increase in FGF-21 serum levels and FGF-21 expression in BAT
compared to wild-type controls (14). This experimental model
of ablation of non-shivering thermogenesis (NST) provided
compelling evidence that FGF-21 acts in an autocrine–paracrine
fashion on BAT, contributing to the adaptive thermogenic
response and browning of WAT, ultimately expanding the NST
capacity.

FGF-21 Function in Human Brown
Adipose Tissue
In 2013, our lab first discovered the effects of mild cold exposure
on circulating FGF-21 levels in healthy humans and its relationship with cold-induced thermogenesis and lipolysis (16). Twelve
healthy volunteers were included in a randomized, single-blind,
crossover intervention study. All subjects were exposed to 24 and
19°C in a whole-room indirect calorimeter for 12 h. EE, plasma
FGF-21, non-esterified fatty acid (NEFA), and adipose tissue
glycerol concentrations were measured. First, we found that plasma
FGF-21 exhibited a two- to threefold diurnal variation at 24°C,
peaking at 0800 hours and progressively dropping to a nadir at
1700 hours, before rising at 1900 hours. We next compared in the
same volunteers FGF-21 levels in blood samples obtained at 24°C
and at 19°C. The diurnal rhythm of plasma FGF-21 concentration
was retained at 19°C; however, the rise in FGF-21 levels in the late
afternoon observed at 24°C was not. Plasma FGF-21 concentration
was significantly higher at 19°C compared with 24°C at paired time
points of cold exposure. Compared with 24°C, at 19°C the FGF-21
area-under-the-curve (AUC) was significantly increased. Also, the
change in adipose tissue microdialysate glycerol concentrations
between 19 and 24°C correlated positively with the change in
plasma FGF-21 levels, but not the change in serum NEFA AUC.
Total energy expenditure (TEE, or EE) was significantly higher
at 19°C compared with 24°C, and the change in plasma FGF-21
concentration correlated positively with the change in EE. In a
multivariate analysis, the change in plasma FGF-21 concentrations
predicted the change in TEE. Collectively, our study demonstrated
that mild cold exposure elevates circulating FGF-21 levels in
humans. Augmented FGF-21 levels correlated positively with

Molecular Mechanisms of FGF-21-Induced
Thermogenesis
The mechanisms which mediate the induction of Fgf21 gene
expression in response to cold were also investigated by Hondares
et al. (13). Norepinephrine, a main mediator of cold-induced
thermogenic activation of BAT, significantly induced Fgf21
expression in cultured, differentiated mouse brown adipocytes.
The same response was observed in brown adipocytes treated
with cyclic adenosine monophosphate (cAMP). The induction
of Fgf21 gene expression by either norepinephrine or cAMP in
brown adipocytes led to a significant increase in the release of
FGF-21 into the cell culture medium. Treatment of brown adipocytes with propranolol, a β-adrenergic antagonist, successfully
suppressed the effects of norepinephrine on Fgf21 gene expression, whereas prazosin, an α-adrenergic inhibitor, had no effect.
Furthermore, treatment with a protein kinase A (PKA) inhibitor
(H89) or p38 mitogen-activated protein kinase (MAPK) inhibitor
(SB202190) suppressed the induction of Fgf21 gene expression by
norepinephrine. These results indicate that norepinephrine acts
through β-adrenergic receptors to increase cAMP levels, causing
Frontiers in Endocrinology | www.frontiersin.org
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increments of adipose tissue microdialyzate glycerol and TEE
during cold exposure. To our knowledge, this was the first study
revealing potential regulatory links between FGF-21, lipolysis, and
cold-induced thermogenesis in humans.
More recently, we explored cold exposure-induced FGF-21
secretion in humans and compared it with FNDC5 (also termed
Irisin) (17). To elucidate whether BAT is a significant source of
cold-augmented FGF-21 secretion, we profiled FGF-21 levels in
five healthy men, stratified by BAT status, during 5 h of either a
mildly cold non-shivering condition (19°C) or thermoneutrality
(24°C). Consistent with our previous findings, diurnal reduction
of FGF-21 was blunted at 19°C. However, the blunting effect was
markedly greater in BAT-positive subjects compared to BATnegative subjects, translating to a total FGF-21 output more than
sixfold higher in BAT-positive individuals. Since the subjects
were of similar age and body composition, and differed only by
BAT status, these associative results support BAT as a source
of FGF-21 during cold exposure in humans. Interestingly, the
biorhythm of FGF-21 was virtually identical when subjects were
exposed to warm temperature (27°C), and we observed a trend
between FGF-21 diurnal reduction and shivering intensity (17).
We next examined the bioenergetic profiles of FGF-21-treated
primary human adipocytes in vitro, which were established
from deep neck fat biopsies, a location known to be enriched
with beige adipocytes (18). FGF-21 treatment increased general
BAT and beige gene expression, without altering expression
levels of classic brown fat lineage genes. UCP1 protein, which
was absent in untreated adipocytes, became strongly expressed
following FGF-21 treatment. During an adipocyte thermogenic
function assay, FGF-21 significantly enhanced adipocyte basal
oxygen consumption rate measured with an extracellular fluid
bioanalyzer. Pharmacological interrogation of mitochondrial
respiration revealed augmentation of both forms of respiratory
uncoupling (oligomycin resistant and maximal) by FGF-21 treatment. Since the primary function of BAT is the generation of heat,
we quantified the heat production from adipocytes directly by
infrared thermography. FGF-21 increased heat production only
after norepinephrine exposure. Thus, not only norepinephrine is
required for FGF-21 induction and release in BAT (13), it is also
required for FGF-21-induced thermogenesis in BAT. In contrast,
FNDC5 treatment enhanced adipocyte heat production dose
dependently, and was further increased by norepinephrine (17).
Most recently, serum FGF-21 levels were correlated with BAT
activity in humans (19). A total of 59 lean and healthy subjects were
included in two different cooling protocols: air-cooling (20, 21)
and water-perfused suit (22, 23), followed by a [18F]FDG-PET/CT
scan as a measure for BAT activity. In agreement with our previous
study, serum FGF-21 levels were positively correlated with human
cold-induced BAT activity. Interestingly, this was observed only in
men, although BAT is more likely to be detected in females than
in males (24). In contrast to our previous studies, the authors did
not find an effect of acute cold exposure on plasma FGF-21 levels,
but did observe an increase after a 10-day cold acclimation period,
in parallel with upregulation of BAT activity. These results further
support a role for FGF-21 as a cold-induced activator and product
of BAT. Additionally, basal FGF-21 levels correlated positively with
the change in core body temperature upon cold exposure for both
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males and females in both the water-cooling group and the aircooling group. This result suggests that in humans, FGF-21 may
play a novel role in maintaining core body temperature in response
to reduced ambient temperature.

Metabolic Benefits of an FGF-21 Analog
In a clinical setting, elevated serum FGF-21 levels have been observed
in obese, glucose intolerant, and diabetic patients (25–27). FGF-21
levels are positively correlated with adiposity, plasma glucose, and
insulin levels (indices of insulin resistance and triglyceride (TG)
levels), and negatively correlated with high-density lipoprotein
cholesterol (HDL-C) (28). So far, no data are available on direct
administration of native FGF-21 to humans; however, a FGF-21
analog (LY2405319) has shown promise in obese human subjects
with type 2 diabetes (29, 30). LY2405319 is a biopharmaceutical
optimization of native FGF-21 with enhanced physical stability, and
is able to maintain biological potency in vivo more successfully than
the native molecule (31). During a clinical study, LY2405319 (3, 10,
20 mg/kg/day) was injected subcutaneously for 28 days. Compared
with placebo, the 10 and 20 mg groups showed reductions in lowdensity lipoprotein cholesterol (LDL-C) by 29.5 and 20.2%, respectively. An additional significant decrease in mean fasting TG levels
appeared as early as day 2 for all three dosing groups. The reduction
in fasting TG levels was maintained for the entire treatment period
and was significantly different from baseline and placebo at the 10
and 20 mg dosage levels. Total cholesterol concentrations were also
lowered in the 10 (−19.2%) and 20 mg/kg/day (−15.4%) groups.
Additionally, an increase of 15–20% in HDL-C occurred across all
three dosage groups. Compared with baseline, both 10 and 20 mg
dosage groups had a significant decrease in body weight (−1.75 and
−1.49 kg). There was a trend of lower glucose levels in all dosage
groups, and fasting insulin levels were significantly reduced in the
20 mg dose group when compared to baseline. In mice, FGF-21
administration lowered body weight and increased metabolic rate
without suppressing food intake (11). In the human clinical study,
neither caloric intake nor EE were measured. However, the significant increase in β-hydroxybutyrate in all LY2405319-treated
groups suggests that TEE might have been increased, since
β-hydroxybutyrate has a substantial thermic effect in humans,
leading to an increase in EE (32). Thus, it would appear that despite
elevated baseline FGF-21 levels (“FGF-21 resistance”), obese individuals with type 2 diabetes may still benefit from administration
of an FGF-21 analog. Future studies are still needed to determine
the potential metabolic benefits of interventions, which increase
endogenous FGF-21 levels in this population.

Metabolic Benefits of FGF-21 May Be
“Browning” Independent
Brown adipose tissue has been increasingly recognized as a
natural target for the modulation of EE. This tissue is very different from a white fat depot, in that it requires the uptake of
free fatty acids and glucose for activation and expends energy
instead of storing it (33). Although the most important functions
of BAT in small mammals are thermogenesis and maintenance
of core body temperature, more recent evidence has shown that

4

September 2015 | Volume 6 | Article 148

Ni et al.

Metabolic effects of FGF-21

this tissue may represent an important target in humans for the
treatment of obesity (34–36) and type 2 diabetes (37–39). Due
to FGF-21’s function as an important thermogenic regulator, its
role in energy metabolism has also been widely investigated (4,
11, 40, 41). These in vivo studies used ob/ob, db/db, diet-induced
obese, and FGF-21 transgenic mice models. FGF-21 transgenic
mice had significantly lower body weight, fasting glucose levels,
and hepatic fat deposition. They also retained more BAT, had
subcutaneous adipocytes of smaller size, and exhibited improved
glucose clearance and insulin sensitivity when compared to
control littermates. Pharmacologic administration of FGF-21
dose dependently (0.1–10 mg/kg/day) reduced body weight and
whole-body fat mass in diet-induced obese mice by increasing EE
and physical activity levels. In diet-induced obese mice, FGF-21
also reduced blood glucose, insulin, and lipid levels, and reversed
hepatic steatosis. Similarly, FGF-21 administration improved
hepatic and peripheral insulin sensitivity in both lean and dietinduced obese mice, independent of a reduction in body weight
and adiposity. Finally, it is worth noting that exogenous FGF-21
can promote reductions in fasting glucose levels, body weight,
and circulating lipid levels in obese diabetic rhesus monkeys (42).
Recently, it has been debated whether the metabolic benefits
of FGF-21 are “browning” and UCP1 dependent (43–45). These
articles highlight a common pharmacological role for FGF-21
independent from BAT, since FGF-21 is effective in UCP1 null
mice to reduce food intake for the promotion of weight loss.
The majority of FGF-21-driven metabolic endpoints seem to
not require UCP1 nor white adipocyte browning (brite or beige
adipocytes); the browning of WAT by FGF-21 is dependent on
temperature and diet, and UCP1 is only essential for helping
FGF-21 regulate EE. These results are not surprising because
FGF-21 acts through a cell-surface receptor complex composed
of conventional FGFRs and beta-klotho (3, 46, 47). It is worth
noting that both beta-klotho and FGFR1 are expressed not only
in adipose tissue, but also in the liver and pancreas (48–50). Betaklotho is also expressed in the suprachiasmatic nucleus (SCN)
of the hypothalamus and the dorsal vagal complex (DVC) of the
hindbrain in mice and this expression allows FGF-21 to regulate
circadian behavior and metabolism at the level of the central
nervous system (CNS) (51). Interestingly, the same study noted
that the metabolic effects of FGF-21 overexpression to reduce
blood glucose and insulin levels required beta-klotho expression
in the SCN. This suggests that the CNS is pivotal in modulating
the metabolic actions of FGF-21 in peripheral tissues, such as
the liver and adipose tissue, and future studies are necessary to
elucidate these pathways.
Skeletal muscle is also a target tissue for FGF-21 function (45,
52, 53). Skeletal muscle is strongly dependent on oxidative phosphorylation for energy production, and at the same time, skeletal
muscle insulin resistance in type 2 diabetes and obesity involves
dysregulation of the oxidation of both carbohydrate and lipid fuels.
A recent study showed that in skeletal muscle from subjects with
mitochondrial disorders, there was an increase in FGF21 expression
likely representing a compensatory mechanism (54). FGF21 was
induced in the skeletal muscle tissue of patients with mitochondrial
oxidative phosphorylation deficiency and compensated for the
metabolic energy deficiency by mammalian target of rapamycin
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(mTOR) activities, which serve as a master regulator of cell metabolism and energy homeostasis (55) via the PI3K–Akt pathway in
skeletal muscle cells. mTOR can also increase the expression levels
of YY1 and PGC-1α, resulting in enhanced mitochondrial oxidative
function. FGF-21-enhanced mitochondrial function was also demonstrated by significant increases in mitochondrial ATP synthesis,
oxygen consumption rate, glycolytic capacity, activity of citrate
synthase, and expression of key energy metabolism genes, such as
Glut1, Cpt1a, Cpt2, Cycs, and Idh3a. All of these regulatory changes
and recent insights into FGF-21 signaling in the brain contribute to
the new role of FGF-21 in lipid and glucose metabolism, independent of thermogenesis or WAT “browning.”

Concluding Remarks and Future
Perspectives
Fibroblast growth factor-21 is a pleiotropic metabolic regulator
which can reverse obesity and diabetes in different animal models
and whose pharmacologic effects can be “browning” or UCP1independent. In humans, a FGF-21 analog administration results
in important metabolic effects, but further studies are required
to elucidate the exact mechanisms of FGF-21 action. By taking
advantage of dense phenotyping techniques with quantitative
functional imaging of BAT, we hope to investigate whether or not
individuals with greater initial BAT abundance or induced beige
fat will have differential metabolic benefits during treatment with
FGF-21 or its analogs (Figure 1).

FIGURE 1 | Hypothetical metabolic benefits of FGF-21 in BAT-positive and
BAT-negative individuals. Green blocks indicate theoretical baseline metabolic
benefits without FGF-21 or analog administration. At baseline BAT-positive
individuals are expected to exhibit greater beneficial metabolic profiles than their
BAT-negative counterparts. Yellow blocks indicate potential changes to baseline
metabolic benefits after FGF-21 or analog administration. The presence and
magnitude of these changes in both BAT-positive and BAT-negative patients have
yet to be elucidated and are a target of future research.
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